Boothbay Fund Management’s Structure Therapeutics GPCR Stock Holding History

Boothbay Fund Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-43,674	Closed	-$1.22M	–	2105
2025 Q3	$1.22M	Sell	43,674 -13,948	-24%	-$278K	0.02%	750
2025 Q2	$1.2M	Sell	57,622 -19,672	-25%	-$433K	0.02%	628
2025 Q1	$1.34M	Sell	77,294 -5,854	-7%	-$143K	0.04%	535
2024 Q4	$2.25M	Buy	83,148 +49,485	+147%	+$1.76M	0.06%	418
2024 Q3	$1.48M	Buy	+33,663	New	+$1.3M	0.03%	626
2023 Q4	–	Sell	-27,981	Closed	-$1.41M	–	1774
2023 Q3	$1.41M	Buy	+27,981	New	+$902K	0.03%	619

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Boothbay Fund Management's GPCR Position: Q4 2025 in Review

Boothbay Fund Management sold out of Structure Therapeutics (GPCR) in Q4 2025, closing a stake of 43,674 shares — an estimated $1.22M sold.

Boothbay Fund Management first reported a position in GPCR in Q3 2023 and held it in 6 quarters. The position peaked at $2.25M in Q4 2024. 197 funds tracked by Wall St. Rank hold GPCR as of Q4 2025.

Boothbay Fund Management reported no remaining Structure Therapeutics position as of Q4 2025 after selling out during the quarter.
Boothbay Fund Management sold 43,674 Structure Therapeutics shares in Q4 2025, an estimated $1.22M.
Boothbay Fund Management first reported a position in Structure Therapeutics in Q3 2023 and held it in 6 quarters.
Boothbay Fund Management's Structure Therapeutics position peaked at $2.25M in Q4 2024.
197 funds tracked by Wall St. Rank held Structure Therapeutics as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.